Drug facts

Tirzepatide for sleep apnea

Reviewed August 2026

It is on the label as an indication¹

Section 1 lists two indications. The second is to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Both indications are stated as being in combination with a reduced-calorie diet and increased physical activity, which is part of the indication rather than a footnote to it.

Two boundaries are worth reading exactly. The indication is for moderate to severe OSA, and it is for adults with obesity. It is not an indication for snoring, for mild OSA, or for sleep apnea in a person without obesity.

What the trials measured²

Efficacy was evaluated in a master protocol trial, NCT05412004, containing two randomized, double-blind, placebo-controlled trials of 52 weeks — called Study 5 and Study 6 on the label. Together they enrolled 469 adults with moderate to severe OSA, defined as an apnea-hypopnea index of 15 or more, and obesity defined as a BMI of 30 or above. Participants with type 2 diabetes were excluded, and everyone received counseling on a reduced-calorie diet and increased physical activity.

The two trials differ in one respect that is the whole reason there are two:

Study 5 (234 patients)

Adults who were unable or unwilling to use positive airway pressure therapy.

Study 6 (235 patients)

Adults who were on PAP therapy, and who were instructed to suspend it for seven days before the primary endpoint was assessed.

Baseline severity was high in both: a mean AHI of 51.5 events per hour in Study 5 and 49.5 in Study 6. These were not borderline cases.

The results at week 52²

The 95% confidence intervals on the treatment differences were −25.8 to −14.2 in Study 5 and −29.6 to −17.9 in Study 6, and the label reports a reduction in AHI irrespective of age, sex, ethnicity, baseline BMI or baseline OSA severity. The last row is the one to read slowly: remission or mild non-symptomatic OSA was defined as an AHI below 5, or an AHI of 5 to 14 with an Epworth Sleepiness Score of 10 or less. Roughly half of treated participants in Study 6 met it — and so did about one in seven on placebo.

The published trial agrees with the label³

SURMOUNT-OSA was published in the New England Journal of Medicine in October 2024, and its figures are the label’s figures — compared one against the other rather than assumed to match. The same −25.3 and −5.3 in trial 1, the same −29.3 and −5.5 in trial 2, the same treatment differences of −20.0 and −23.8, the same confidence intervals.

The publication adds the secondary endpoints in one place: alongside AHI, tirzepatide reduced body weight, hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure, and improved sleep-related patient-reported outcomes. It records that the most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity.

1. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024 Oct 3;391(13):1193-1205. PMID 38912654. NCT05412004.

What the trials deliberately did not test²

The label contains one sentence that most coverage of these results leaves out, and it is the most practically important sentence in section 14.2: the clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.

Study 6 asked people to suspend PAP for seven days so that the sleep study could measure their untreated AHI. That is a measurement protocol. It is not a finding that anyone can stop using their machine, and the label says so in as many words. Anything you read that turns these results into a reason to give up PAP is going beyond what these trials measured.

Adverse reactions in these trials⁴

The label reports adverse reactions separately for the OSA program: 467 of the 469 enrolled participants received at least one dose, and the reactions observed were similar to those reported in the two pooled weight-reduction trials. The difference between 469 and 467 is not an error — two participants in Study 6 were randomized but never received study drug.

What that similarity means in practice is on the table of reactions reported in 5% or more of participants, which is overwhelmingly gastrointestinal. Two of the entries there have their own pages here: fatigue, at 5% to 7% against 3% on placebo, and hair loss, at 4% to 5% against 1%.

What a compounded vial changes¹

Where to take this⁵

To a prescriber, and to whoever manages your sleep apnea if that is a different person. OSA is diagnosed and graded by a sleep study, and every number on this page is anchored to one; none of it can be applied to a person who has not had one. Where any of this can legally be dispensed as a compounded preparation is a separate question, set out in the current legal status of compounded tirzepatide.